News

Video

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

Author(s):

Aditya Bardia, MD

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.

Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Samilia Obeng-Gyasi, MD, MPH,
Nan Chen, MD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

breast
May 28th 2024

Neoadjuvant Pembrolizumab/Chemo, Adjuvant Pembrolizumab Boosts OS in High-Risk Early TNBC

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Breast Cancer
May 23rd 2024

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO
May 23rd 2024

State of the Science Summit - Breast Cancer: Chaired by Suzanne B. Coopey, MD, FACS, and Christie J Hilton, DO